Transaction Overview - Nikita Shah, executive vice president of Amneal Pharmaceuticals, exercised 131,856 stock options and sold the same number of shares for a transaction value of $1.6 million [2][3] - The transaction was executed on November 12 at a weighted average price of $11.92 per share, with no shares retained from the option exercise [4] Insider Holdings Impact - The shares sold represented 47% of Shah's pre-transaction direct holdings, reducing her position from 278,259 to 146,403 shares [5] - This sale is significantly larger than the recent median sell transaction size of 71,694 shares and reflects a higher proportion of holdings compared to the historical sell-only median of 15% [6] Market Context - On the transaction date, Amneal Pharmaceuticals shares closed at $11.90, with a total return of 39% over the prior 12 months [7] - The remaining direct holdings of Shah are valued at approximately $1.7 million based on the November 12 close [7] Company Overview - Amneal Pharmaceuticals has a market capitalization of $3.7 billion and a trailing twelve months (TTM) revenue of $2.9 billion [8] - The company reported a net income of $5.9 million and a 1-year price change of 43% as of the last trading day [10] - Amneal specializes in generic and specialty drugs, serving a diverse range of clients including wholesalers, hospitals, and government agencies, which supports its competitive position in the pharmaceutical industry [10]